Aprea Therapeutics Inc (NAS:APRE)
$ 3.3 0.16 (5.1%) Market Cap: 17.07 Mil Enterprise Value: -11.72 Mil PE Ratio: 0 PB Ratio: 0.78 GF Score: 37/100

Aprea Therapeutics Inc R&D Update - Corporate Call Transcript

Apr 22, 2021 / 05:00PM GMT
Release Date Price: $90.8 (-0.66%)
Operator

Thank you for standing by, and welcome to the Aprea Therapeutics R&D Update. I'd now like to introduce your host for today's program, Chris Schade of Aprea Therapeutics.

Christian S. Schade
Aprea Therapeutics, Inc. - President, CEO & Chairman

Thank you, operator, and good afternoon, everyone. This is Chris Schade, the CEO of Aprea Therapeutics. And on behalf of the entire Aprea team, I'd like to welcome you all to our virtual R&D Day presentation. I'm joined today for our presentation by Dr. Eyal Attar, our Chief Medical Officer.

And before we get started, some administrative details. We intend to answer questions at the end of the prepared remarks. Please feel free to submit a question at any time during the presentation by clicking on the Ask A Question in the right top corner of your browser window. Type a question into the question box and click Submit. Also, a replay of today's webcast will be archived immediately following the conclusion of the presentation and will be found on the Investor & Media section of our website, aprea

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot